Neo-adjuvant therapy for pancreatic cancer: hope for the future

References

• Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Ervik M, Lam FColombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [25 Dec 2018
   Google Scholar
• Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;
   Google Scholar
• Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018, Dec, 20; 379(25): 2395–2406.
   PubMed Web of Science ®Google Scholar
• Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005 Jun;7(5):189–197.
   PubMedGoogle Scholar
• Desai NV, Sliesoraitis S, Hughes SJ, et al. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med. 2015 Aug;4(8):1224–1239.
   PubMed Web of Science ®Google Scholar
• Riall TS, Nealon WH, Goodwin JS, et al. Outcomes following pancreatic resection: variability among high volume providers. Surgery. 2008;144:133–140.
   PubMed Web of Science ®Google Scholar
• Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreatiocuodenectomies. Ann Surg. 2006;244(1):10–15.
   PubMed Web of Science ®Google Scholar
• Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol. 2008l;15:2773–2786.
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, et al. Pancreatic Cancer. Lancet. 2004;363:1049–1057.
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Ko CY, Bentrem DJ. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260:372–377.
   PubMed Web of Science ®Google Scholar
• Kazanjian KK, Hines OJ, Eibl G, et al. Management of Pancreatic fistulas after pancreaticoduodenectomy. Arch Surg. 2005;140(9):849–855.
   PubMedGoogle Scholar
• Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466–473.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. NEngl J Med. 2011 May 12;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Jameson GS, Borazanci EH, Babiker HM, et al. A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. J Clin Oncol. 2017;35:341.
   Google Scholar
• Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLOS Med. 2010, Apr 20;7(4):e1000267.
   PubMed Web of Science ®Google Scholar
• Fathi A, Christians KK, George B, et al. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015;6(4):418–429.
   PubMed Web of Science ®Google Scholar
• Verma V, Li J, Lin C. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality and complications. Am J Clin Oncol. 2016;39:302–313.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug;15(8):1028–1061.
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008 Apr;12(4):701–706.
   PubMed Web of Science ®Google Scholar
• Roder JD, Thorban S, Pantel K, et al. Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. World J Surg. 1999 Sep;23(9):888–891.
   PubMed Web of Science ®Google Scholar
• Haeno H, Gonen M, Davis MB, et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012, Jan 20;148(1–2):362–375.
   PubMed Web of Science ®Google Scholar
• Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008, Jul 20;26(21):3503–3510.
   PubMed Web of Science ®Google Scholar
• Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol. 2008, Jul 20;26(21):3511–3516.
   PubMed Web of Science ®Google Scholar
• Simons JP, Ng SC, McDade TP, et al. Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices. Cancer. 2010, Apr 1;116(7):1681–1690.
   PubMed Web of Science ®Google Scholar
• Merchant NB, Rymer J, Koehler EA, et al. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg. 2009, May;208(5):829–838. discussion 838–41.
   PubMed Web of Science ®Google Scholar
• Kent TS, Sachs TE, Sanchez N, et al. Conditional survival in pancreatic cancer: better than expected. HPB (Oxford). 2011 Dec;13(12):876–880.
   PubMed Web of Science ®Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985 Aug;120(8):899–903. Erratum in: Arch Surg 1986 Sep;121(9):1045.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013, Oct 9;310(14):1473–1481.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. European study group for pancreatic cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017, Mar 11;389(10073):1011–1024.
   PubMed Web of Science ®Google Scholar
• Katz MH, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008 Mar/Apr;58(2):111–125.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017, Feb 10;35(5):515–522.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Tajima H, Makino I, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma. Anticancer Res. 2018 Jan;38(1):337–343.
   PubMed Web of Science ®Google Scholar
• Evan GI, Hah N, Littlewood TD, et al. Re-engineering the pancreas tumor microenvironment: a ‘Regenerative Program’ Hacked. Clin Cancer Res. 2017, Apr 1;23(7):1647–1655.
   PubMed Web of Science ®Google Scholar
• Seufferlein T, Bachet JB, Van Cutsem E, et al., ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23(Suppl 7):vii33–40.
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with folfirinox followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018, Jul 1;4(7):963–969.
   PubMed Web of Science ®Google Scholar
• Christians KK, Heimler JW, George B, et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016 Mar;159(3):893–900.
   PubMed Web of Science ®Google Scholar
• Reni M, Balzano G, Zanon S, et al. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016;115(3):290–296.
   PubMed Web of Science ®Google Scholar
• Van Tienhoven G, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. 2018 ASCO Annual Meeting; June 4, 2018. Chicago, IL, USA.  Abstract LBA4002. Presented.
   Google Scholar
• Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008 Sep;19(9):1592-9.
   Web of Science ®Google Scholar
• Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007, Jan 20;25(3):326–331.
   PubMed Web of Science ®Google Scholar
• Sanders MK, Moser AJ, Khalid A, et al. EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc. 2010 Jun;71(7):1178–1184.
   PubMed Web of Science ®Google Scholar
• Rudra S, Jiang N, Rosenberg SA, et al. High dose adaptive MRI guided radiation therapy improves overall survival of inoperable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2017;99(Issue 2):E184.
   Google Scholar
• Campbell WG, Jones BL, Schefter T, et al. An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol. 2017 Jul;124(1):168–173.
   PubMed Web of Science ®Google Scholar
• Guss ZD, Rosati LM, Hsu CC, et al. Neoadjuvant stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: prognostic factors for local recurrence and survival. Int J Radiat Oncol Biol Phys. 96(Issue 2):E212- E213.
   Web of Science ®Google Scholar
• Perni S, Kim P, Yanagihara T, et al. Stereotactic body radiotherapy for pancreatic cancer: analysis of toxicity. J clin oncol. 2017;35(4_suppl):436.
   Web of Science ®Google Scholar
• Ishikawa O, Ohigashi H, Imaoka S, et al. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. Arch Surg. 1991 Jul;126(7):885-9.
   Google Scholar
• Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017, Nov 1;28(11):2786–2792.
   PubMed Web of Science ®Google Scholar
• Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2017;
   Web of Science ®Google Scholar
• Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990 Apr;85(4):350–355.
   PubMed Web of Science ®Google Scholar
• Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg. Oncol. 2007 Apr;33(3):266–270.
   PubMed Web of Science ®Google Scholar
• Williams JL, Kadera BE, Nguyen AH, et al. CA19-9 normalization during pre-operative treatment predicts longer survival for patients with locally progressed pancreatic cancer. J Gastrointest Surg. 2016 Jul;20(7):1331–1342.
   PubMed Web of Science ®Google Scholar
• Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May;16(5):430–438.
   PubMed Web of Science ®Google Scholar
• Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994 Nov;35(11):1771–1776.
   PubMed Web of Science ®Google Scholar
• Kang CM, Lee SH, Hwang HK, et al. Preoperative volume-based PET parameter, MTV2.5, as a potential surrogate marker for tumor biology and recurrence in resected pancreatic cancer. Medicine (Baltimore). 2016 Mar;95(9):e2595.
   PubMed Web of Science ®Google Scholar
• Mellon EA, Jin WH, Frakes JM, et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017 Mar;56(3):391–397.
   PubMed Web of Science ®Google Scholar
• Borazanci E, Dang CV, Robey RW, et al. Pancreatic Cancer: ‘A Riddle Wrapped in a Mystery inside an Enigma’. Clin Cancer Res. 2017 Apr 1;23(7):1629–1637.
   PubMed Web of Science ®Google Scholar
• Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014, Sep 25;159(1):80–93.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
   PubMed Web of Science ®Google Scholar
• Dreyer SB, Pinese M, Jamieson NB, et al. Australian pancreatic cancer genome initiative; glasgow precision oncology laboratory.precision oncology in surgery: patient selection for operable pancreatic cancer. Ann Surg. 2018, Nov 30. [ Epub ahead of print].
   PubMedGoogle Scholar
• Ohara Y, Chew SH, Misawa N, et al. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. Oncotarget. 2018, Apr 6;9(26):18494–18509.
   PubMedGoogle Scholar
• Picozzi VJ, Pishvaian MJ, Mody K, et al. Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients. J Clin Oncol. 2018;36(suppl):abstr 4016.
   Google Scholar